Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

10 richest women in India in 2024

<keyword id="6354512" type="General" weightage="100" keywordseo="infosys" source="Orion">Infosys</keyword> on Thursday announced the retirement of <keyword id="1440" type="General" weightage="80" keywordseo="kiran" source="Orion">Kiran</keyword> Mazumdar-Shaw as <keyword id="6390711" type="General" weightage="80" keywordseo="independent" source="Orion">Independent</keyword> Director from its Board, effective March 22, 2023, upon completion of her tenure. Accordingly, the Board has appointed D <keyword id="120337" type="General" weightage="80" keywordseo="sundaram" source="Orion">Sundaram</keyword> as the Lead Independent Director of the Company, effective Thursday based on the recommendation of the 'Nomination and Remuneration Committee'. Sundaram has been on the Board of Infosys since 2017. Sundaram serves on the Audit Committee, Risk Management Committee, <keyword id="16919243" type="General" weightage="50" keywordseo="stakeholders-relationship-committee" source="Orion">Stakeholders Relationship Committee</keyword>, Nomination and Remuneration Committee, and Cybersecurity Risk Sub-Committee. "We profusely thank Kiran for having been such an integral member of the Infosys family, providing valuable guidance and leadership to the Board over the years. I am personally very grateful to her as she has been a tremendous ally and amazing colleague on the Board, ever since I re-joined Infosys in August 2017," chairman of Infosys Nandan Nilekani, said. "We also congratulate Sundaram on being appointed as Lead Independent Director and look forward to his continued insight and steadfast support as Infosys continues its growth and transformation journey," Nilekadded. Kiran Mazumdar-Shaw was appointed to the Infosys' Board as an Independent Director in 2014, and as Lead Independent Director in 2018. She also served as the Chairperson of the 'Nomination &amp; Remuneration Committee' and 'CSR Committee', and as a member of the 'Risk Management and ESG Committees' of the Board. "The Board places on record its appreciation for Ms Shaw's invaluable contribution, guidance, and strategic vision, which has helped the Company build and execute a resilient growth strategy," Infosys said in a release. Kiran Mazumdar-Shaw is the Chairperson and Managing Director of Biocon Limited, a biotechnology company based in Bangalore, India. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/business/news/former-idbi-gm-conspired-with-vijay-mallya-over-short-term-loan-to-kingfisher-airlines-cbi/articleshow/98936880.cms">Former IDBI GM conspired with Vijay Mallya over short term loan to Kingfisher Airlines: CBI</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/finance/banks/news/fm-nirmala-sitharaman-likely-to-meet-psu-banks-heads-on-saturday/articleshow/98936889.cms">FM Nirmala Sitharaman likely to meet PSU banks heads on Saturday</a>

Kiran Mazumdar-Shaw to retire from Infosys board

Global biopharmaceuticals company <keyword id="6358361" type="General" weightage="100" keywordseo="biocon" source="Orion">Biocon</keyword> on Wednesday reported 23 per cent rise in revenue for the first quarter of financial year 2023, at Rs 2,217 crore. "We have had a strong start to the year. At a consolidated level, YoY revenues grew 23 per cent backed by robust growth in both <keyword id="6359687" type="General" weightage="50" keywordseo="biosimilars" source="Orion">Biosimilars</keyword> (29 per cent) and Generics (19 per cent). Core earnings before interest, taxes, depreciation, and amortisation (EBITDA) grew 25 per cent and margin improved to 31 per cent compared to 30 per cent in Q1FY22 and net profit grew 71 per cent to Rs 144 crore. "Our financial performance this quarter includes the impact of annual increments in personnel costs as well as increased input and freight costs, pursuant to pandemic and geopolitical disruptions of global supply chains. "All our three businesses are poised for the next phase of strong and sustainable growth which has been challenged during the two years of the Covid-19 pandemic," <keyword id="14575168" type="General" weightage="50" keywordseo="biocon-and-biocon-biologics-executive" source="Orion">Biocon and Biocon Biologics Executive</keyword> <keyword id="10034873" type="General" weightage="20" keywordseo="chairperson-kiran-mazumdar-shaw" source="Orion">Chairperson Kiran Mazumdar-Shaw</keyword> said. Sales of Glargine in the US, and key biosimilars in emerging markets were the main drivers for <keyword id="14245336" type="General" weightage="50" keywordseo="biocon-biologicals" source="Orion">Biocon Biologicals</keyword>' strong performance. <keyword id="10493627" type="General" weightage="50" keywordseo="biocon-biologics-ltd" source="Orion">Biocon Biologics Ltd</keyword> Managing Director <keyword id="287851" type="General" weightage="50" keywordseo="arun-chandavarkar" source="Orion">Arun Chandavarkar</keyword> said: "Initiation of global clinical trials for two monoclonal antibodies and advancement of our other pipeline assets led to a 120 per cent increase in our research and development investments this quarter. Whilst this impacts EBITDA in the near term, such investments will create a strong portfolio to secure our future growth. "Our strategic alliance with Serum Institute Life Sciences for vaccines and the acquisition of Viatris' global biosimilars business are on track for closure in the second half of this calendar year." SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/india/news/reduction-in-rice-cereals-sown-area-worrisome-bank-of-baroda/articleshow/93175801.cms">Reduction in rice, cereals sown area worrisome: Bank of Baroda</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/tech/news/oppo-pad-air-review-sleek-and-stylish-but-short-on-power/articleshow/93165775.cms">Oppo Pad Air review: Sleek and stylish but short on power</a>

Biocon Q1FY23 revenue up 23% at Rs 2,217 cr

<ul><li><keyword id="6379793" type="General" weightage="100" keywordseo="falguni-nayar" source="Orion">Falguni Nayar</keyword> is the richest self-made billionaire with a net worth of ₹57,520 crore.</li><li>However, <keyword id="1490249" type="General" weightage="20" keywordseo="Roshni-Nadar-Malhotra" source="Orion">Roshni Nadar Malhotra</keyword> of HCL Technologies is the wealthiest woman, as per Kotak Private Banking Hurun list.</li><li>Around 25 new women have entered into the list this year, says the report.</li></ul>It’s beauty over biotech as Falguni Nayar overtook Biocon’s <keyword id="6413985" type="General" weightage="20" keywordseo="kiran-mazumdar-shaw" source="Orion">Kiran Mazumdar-Shaw</keyword> as India’s richest self-made woman with a wealth of ₹57,520 crore, as per Kotak Private Banking Hurun’s list of India’s wealthiest women. Nayar’s ranking went up nine places in the list, after the company she founded, Nykaa, went public last year. Roshni Nadar Malhotra of HCL Technologies however retained her title as the wealthiest woman on the list with ₹84,330 crore, for the second year in a row. Around 25 new women have entered into the list this year, says the report. The report further highlights that the cut-off wealth required to feature in the list has almost tripled since last year to ₹300 crore. The women on the 2021 list have an average wealth of around ₹4,170 crore as against ₹2,725 crore in the last year. “Over the years, Indian women are slowly yet surely coming into their own - carving a space for themselves through knowledge, excellence, passion, and empathy,” said <keyword id="14568875" type="General" weightage="80" keywordseo="oisharya-das" source="Orion">Oisharya Das</keyword>, CEO – private banking, <keyword id="46013" type="General" weightage="50" keywordseo="kotak-mahindra-bank" source="Orion">Kotak Mahindra Bank</keyword>. The list is based on the net worth of women as on 31 st December, 2021. <cmsannotation type="cmsannotation" annotationid="More younger women are becoming self-made billionaires" comment="subhead" text="More younger women are becoming self-made billionaires">More younger women are becoming self-made billionaires</cmsannotation> Even though the founder of Biocon, Shaw, was displaced — her sector pharmaceuticals too saw the most number of new entrants, followed by healthcare and consumer goods. 9 out 20 women under the age of 40 years or younger category are self-made, according to the report. Three professional managers also made it to the list. Pepsico’s <keyword id="6421975" type="General" weightage="80" keywordseo="indra-nooyi" source="Orion">Indra Nooyi</keyword> is the richest professional manager, with a wealth of ₹5,040 crore. And, 33-year-old Kanika Tekriwal of Jetsetgo is the youngest self-made woman. “Women-led wealth creation directly improves women’s employment, corresponding families, and society. Inclusion of women, who represent 50% of India’s population in the workforce or wealth creation, cuts across societal barriers,” said <keyword id="2672295" type="General" weightage="80" keywordseo="anas-rahman-junaid" source="Orion">Anas Rahman Junaid</keyword>, MD and chief researcher at <keyword id="3656834" type="General" weightage="50" keywordseo="hurun-india" source="Orion">Hurun India</keyword>. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/business/telecom/news/5g-spectrum-auctions-big-money-is-in-but-no-bidding-war-yet/articleshow/93156289.cms">5G spectrum auctions: Big money is in but no bidding war yet</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/tech/apps/news/a-massive-data-breach-in-2020-impacted-3-4-million-paytm-usersheres-how-to-find-out-if-your-data-was-compromised/articleshow/93157246.cms">A massive data breach in 2020 impacted 3.4 million Paytm users – here’s how to find out if your data was compromised</a>

Nykaa’s Falguni Nayar overtakes Kiran Mazumdar Shaw as the richest self-made Indian woman

<ul><li>On June 5, Biocon’s Executive <keyword id="9348685" type="PERSON" weightage="20" keywordseo="chairperson-kiran-mazumdar-shaw">Chairperson Kiran Mazumdar Shaw</keyword> was named as <keyword id="9348456" type="UNKNOWN" weightage="20" keywordseo="ey-world-entrepreneur-of-the-year">EY World Entrepreneur of the Year</keyword> 2020. </li><li>With this, she joined Uday Kotak of Kotak Mahindra Bank and Narayana Murthy of Infosys, who were awarded with this honour in 2014 and 2005, respectively. </li><li>She founded the India-based pharma company Biocon with merely two employees and funds worth $500. </li><li>In 2014, Biocon became the first biopharma company to be a publicly-traded entity and the second company to touch the $1 billion mark on the very first day of the listing.</li></ul>In 1978, <keyword id="55796" type="PERSON" weightage="20" keywordseo="Kiran-Mazumdar-Shaw">Kiran Mazumdar Shaw</keyword> founded the India-based pharma company Biocon with merely two employees and funds worth $500. 42 years later, Shaw has been named as <keyword id="9348684" type="UNKNOWN" weightage="20" keywordseo="ey-world-entrepreneur">EY World Entrepreneur</keyword> of the Year 2020. <div type="twitter" handle="EY_EOY" handlename="EY EOY" image="http://pbs.twimg.com/profile_images/877518155282878464/HTnSrpib_normal.jpg" favoritecount="302" retweetcount="123" status="Congratulations to @kiranshaw, Executive Chairperson of India-based @Bioconlimited who is named EY World Entreprene… https://t.co/eYxchprTNh" createdat="1591297093000" id="1268618074879438853"></div> With this, she has joined the likes of Uday Kotak of Kotak Mahindra Bank and Narayana Murthy of Infosys, who were awarded with this honour in 2014 and 2005 respectively. The virtual award ceremony was held on June 5 — and she was chosen from over 46 entrepreneurs from 41 countries. “She has built India's largest biopharmaceutical company on a foundation of compassionate capitalism and putting patient needs before profits,” Chair of the EY World Entrepreneur Of The Year judging panel <a href="https://www.prnewswire.com/in/news-releases/dr-kiran-mazumdar-shaw-from-india-named-ey-world-entrepreneur-of-the-year-tm-2020-883966722.html">said</a>. An aspiring Brewmaster who opened a bio-enzymes company <div type="image" title="eea0f7895182bcc364abaeda35e570da" msid="76208305" hostid="261"></div> Kiran, who graduated from Australia in 1975 wanted to work as a Brewmaster — a person who looks after everything that goes in the process of making a beer. Little did she know, the brewing industry — which is highly male-dominated in India — will not accept a woman in the role. But, that did not stop her. Two years down the line, she started Biocon in a rented house in Bengaluru where they produced the bio enzymes in the garage. A year of struggle and Biocon became the first such company in India that exported enzymes to other countries like the US and Europe. Years later, in 2004, she came up with <keyword id="1829392" type="COMPANY" weightage="20" keywordseo="Biocon-Foundation">Biocon Foundation</keyword> — which aims to provide healthcare and sanitation facilities and diagnosis and treatment of cancer and other non-communicable diseases to weaker sections of the society. Bicon goes public <div type="image" title="06c05f1aefb71a5e6abe2fa9b1bd87fa" msid="76208327" hostid="261"></div> In 2014, Biocon became the first biopharma company to be a publicly-traded entity and the second company to touch the $1 billion mark on the very first day of the listing. Over the years, the bio-enzymes major — which is now one of the prominent biotech giants in Asia — grew multifold to become a <a href="https://www.businessinsider.in/stock-market/news/biocon-share-price-falls-after-earnings-and-mutual-funds-stake-in-the-stock/articleshow/75754048.cms">$5 billion company</a>. Today, Biocon provides healthcare requirements like insulin for diabetes, biosimilars for those fighting cancer, arthritis and other severe diseases. The company reported revenue worth $800 million, as of FY19 and employees more than 11,000 people. In fact, Biocon has created its mark where other pharma giants are struggling and has a presence in over 120 countries. That includes fermentation-based molecules, human insulin, contract research services and more. That may be because of the affordability of the products. In September 2019, Biocon announced the supply of a special kind of insulin to middle income companies on low prices — in fact, less than a third of the current prices. Meanwhile, Shaw has been an angel investor for a lot of startups in the healthcare domain including those in areas like breast cancer screening, chemotherapy and others. In times of the global pandemic While the world is waiting with bated breath for a vaccine to treat coronavirus, Shaw believes that it will take <a href="https://www.businessinsider.in/science/health/news/biocon-chairperson-kiran-mazumdar-shaw-says-indias-covid-19-vaccines-will-enter-clinical-trial-in-9-months/articleshow/75591805.cms">at least nine months for the COVID-19 vaccine to enter clinical trials</a> in India. She also said that there will be multiple waves before the coronavirus curve flattens as community spread remains a key challenge in India. See also: <a href="https://www.businessinsider.in/business/news/mubadala-to-buy-1-85-pc-stake-in-jio-platforms-for-rs-9093-6-cr/articleshow/76205654.cms?upcache=2">Abu Dhabi's Mubadala to buy 1.85% stake in Ambani's Jio Platforms for ₹9093.6 crore</a> <a href="https://www.businessinsider.in/policy/foreign-policy/news/a-former-diplomat-explains-why-four-agreements-will-take-india-and-australia-ties-to-the-next-level/articleshow/76206931.cms">Beyond ‘khichdi’ and ‘samosa’ ⁠— a former diplomat explains why four agreements will take India and Australia ties to the next level</a>

Biocon’s Kiran Mazumdar Shaw, who debuted in the pharma industry with two employees and $500 becomes EY World Entrepreneur of the Year 2020

<ul><li><a href="https://www.businessinsider.in/trendsfestival" data-type="tilCustomLink">Global Trends Festival</a> is one of the world's most prestigious events which will be live from Oct 19-23.</li><li>While nobel laureates, some of the biggest political and corporate icons will provide thought leadership, it's a great platform to network with CXOs from around the world.</li><li><a href="https://www.businessinsider.in/trendsfestival" data-type="tilCustomLink">Global Trends Festival 2020</a> is presented by <a href="https://www.businessinsider.in/trendsfestival" data-type="tilCustomLink"></a><a href="https://aws.amazon.com/" data-type="tilCustomLink">AWS</a>.</li><li>Register for the <keyword id="10088455" type="UNKNOWN" weightage="20" keywordseo="global-trends-festival">Global Trends Festival</keyword> <a href="https://www.businessinsider.in/trendsfestival" data-type="tilCustomLink"></a><a href="https://www.businessinsider.in/trendsform_2020.cms" data-type="tilCustomLink">here</a>.</li></ul> Kiran Mazumdar Shaw is India's richest self-made woman. She started Biocon at the age of 25 and has built it up into the country's largest pharmaceutical company. Her journey to the top was no easy task, but Shaw is known for her thinking and vision. Shaw could foresee the potential and opportunity in the biotech space, and she capitalised on it. Shaw calls herself an "accidental entrepreneur." She wanted to become India's first woman brewmaster. When those plans met with resistance in India, she set her sights on the industrial enzyme-producing business and marched on to conquer the biopharma space in the 90s. In 2014, Biocon was India's first biotech company to go public, and it hit the <a href="https://www.businessinsider.in/thelife/personalities/news/indias-second-richest-woman-kiran-mazumdar-shaw-nearly-doubles-her-wealth-to-4-6-billion-during-the-covid-19-pandemic/articleshow/78569565.cms">$1 billion mark</a> on the day it listed. There has been no looking back since. Kiran Mazumdar Shaw believes that women play an essential role in economic development, and their contribution has been ignored for a long time. "It's a myth to think that women are not bold enough to run daring businesses. It's a myth that all of us have busted time. So, I'm really surprised that the world still doesn't get it," she told <a href="https://www.businessinsider.in/thelife/personalities/news/kiran-mazumdar-shaw-wanted-to-be-a-brewmaster-before-founding-the-largest-biotech-company-in-india/articleshow/74508921.cms">Twitter </a>in an interview earlier this year. A pioneer of the biotech industry in India, Shaw has been conferred upon with Padma Shri and the Padma Bhushan. She believes that entrepreneurship is not about making the moolah but having a purpose, and one must always think about giving back to society. In fact, Shaw can tell the Covid-19 story as a survivor and a healer. After all, she has the first-hand experience — as the 67-year old tested positive in mid-August and recovered by the end of the month. And her $7 billion company, Biocon's repurposed drug, Itolizumab, is used to treat the dreaded virus for emergency cases. However, the drug is not a part of the government's clinical management protocol for COVID-19 treatment yet. At the Global Trends Festival 2020, Shaw will share insights on why entrepreneurs must be risk-takers, her journey as a businesswoman, and unlocking India's suppressed potential. SEE ALSO: <a href="https://www.businessinsider.in/trendsfestival" data-type="tilCustomLink"></a><a href="https://www.businessinsider.in/business/news/guenter-butschek-will-speak-about-the-much-needed-electric-push-towards-a-greener-future-at-the-global-trends-festival/articleshow/78642212.cms" data-type="tilCustomLink">Guenter Butschek will speak about the much needed electric push towards a greener future at the Global Trends Festival</a> <a href="https://www.businessinsider.in/trendsfestival" data-type="tilCustomLink"></a><a href="https://www.businessinsider.in/business/news/hear-and-learn-from-byju-raveendran-the-man-who-made-online-classes-fun-years-before-covid-at-the-global-trends-festival-2020/articleshow/78641694.cms" data-type="tilCustomLink">Hear and learn from Byju Raveendran, the man who made online classes fun, years before COVID, at the Global Trends Festival 2020</a> <a href="https://www.businessinsider.in/trendsfestival" data-type="tilCustomLink"></a><a href="https://www.businessinsider.in/business/news/dont-miss-rana-daggubati-speak-about-the-future-of-storytelling-at-the-global-trends-festival-2020/articleshow/78630087.cms" data-type="tilCustomLink">Don’t miss Rana Daggubati speak about the future of storytelling at the Global Trends Festival 2020</a>

Catch Kiran Mazumdar Shaw at the Global Trends Festival 2020, speak about unlocking India's suppressed potential

<ul><li>Half of the billionaires, including Mukesh Ambani, Radhakishan Damani, Gautam Adani, Cyrus Poonawalla, saw significant gains in their wealth. </li><li>The biggest percentage gainer was 67-year old Kiran Mazumdar-Shaw, Biocon founder and the second richest woman in India. </li><li>While Biocon has joined the race to discover the vaccine, Shaw was not immune to COVID-19. She tested positive in August and recovered in a fortnight. </li></ul>India’s super-rich club of 100 people has added nine new faces and about $88 billion collectively during the coronavirus pandemic — which is assumed to be far worse than the Great Depression. Half of the billionaires, including Mukesh Ambani, Radhakishan Damani, Gautam Adani, Cyrus Poonawalla saw significant gains — taking the collective net worth of 100 billionaires to $517.5 billion, <a href="https://www.forbes.com/sites/naazneenkarmali/2020/10/07/indias-100-richest-2020-collective-net-worth-of-countrys-richest-rose-14-despite-pandemic/#2cf4d5e93da4">Forbes reported. </a> The biggest percentage gainer was 67-year old Kiran Mazumdar-Shaw, Biocon founder and the second richest woman in India. Her wealth has nearly doubled from $2.38 billion in 2019 to $4.6 billion in 2020 — a whopping 93.28% gain among India's 100 richest. She is one of the only five women billionaires in India. <keyword id="55796" type="PERSON" weightage="20" keywordseo="Kiran-Mazumdar-Shaw">Kiran Mazumdar Shaw</keyword> started her Indian-based pharma company about 42 years ago with merely two employees and $500 funds. However, it was not until 2014 that her company became a publicly-traded entity. It touched the $1billion mark on the very day it listed. Over the past decade, Biocon has grown by leaps and bounds to become a $5 billion company. In just the last 12 months, Biocon’s share price has surged 99% from ₹233 in October 2019 to ₹464.70 currently. <div type="image" title="Biocon11" msid="78569590" hostid="261"></div> While her company has joined the race to discover a vaccine to fight the virus, Shaw wasn’t immune to it. On August 16, she tested positive for COVID-19 and recovered 15 days later. Shaw has been vocal about leveraging science to contain the virus. Three months after coronavirus broke out in India, Biocon announced that it would launch biologic drug Itolizumab for the treatment of moderate to severe COVID-19 patients at a price of around ₹8,000 per vial. The pharmaceutical is set to begin the phase-4 trials of the potential drug. Well, Shaw might have gained the most, but Mukesh Ambani’s record gains have left everyone behind. He remains India’s richest man for the 13th year in the running and leads by a large margin. Ambani added $37.3 billion to his fortune, thanks to the trail of investments in Reliance Jio and his retail venture. Jio alone got $20 billion investments from investors like Google, Facebook, and Microsoft. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/business/corporates/news/tcs-beats-accenture-to-become-the-worlds-most-valuable-it-services-company/articleshow/78566487.cms">TCS beats Accenture to become the world’s most valuable IT services company — but this not the first time it has raced ahead</a>

India’s second richest woman nearly doubles her wealth to $4.6 billion during the COVID-19 pandemic

<ul><li>Coronavirus vaccines by the <keyword id="150557" type="ORGANIZATION" weightage="20" keywordseo="University-of-Oxford">University of Oxford</keyword> and China are in the most advanced clinical phase and likely the best choice for India according to <keyword id="6358361" type="DEFINITION" weightage="20" keywordseo="biocon">Biocon</keyword> founder <keyword id="55796" type="PERSON" weightage="20" keywordseo="Kiran-Mazumdar-Shaw">Kiran Mazumdar Shaw</keyword>. </li><li>The US <keyword id="8624004" type="UNKNOWN" weightage="20" keywordseo="coronavirus-vaccine">coronavirus vaccine</keyword> candidates may be more talked about but they will likely be much more expensive. </li><li>“We’re much more comfortable with a jab and a low-cost vaccine, which is what the Oxford and Chinese vaccines are all about,” explained Shaw. </li></ul>Biotechnology companies around the world are going head-to-head to create the <keyword id="9171829" type="UNKNOWN" weightage="20" keywordseo="first-coronavirus-vaccine">first coronavirus vaccine</keyword> as the ongoing pandemic continues to wreak havoc on normal life. Some have a headstart over others. “I think the Oxford vaccine and Chinese vaccine are certainly in the more advanced clinical phase as is the German vaccine. The two US vaccines are, of course, much talked about but we really don’t know whether these RNA vaccines will really work like they’re considered to,” Biocon founder Kiran Mazumdar Shaw told Business Insider as a part of its special series ‘Hangout with BI’. <div type="javascript" title="Custom" contenttype="Video"><cdata><![CDATA[]]></cdata></div> From passive vaccines with RNA and DNA-based approaches to active vaccines, each has its pros and cons. “If you talk about mRNA vaccine, yes, there’s some advantage there but the issue with side-effects is also different,” explained <keyword id="9193157" type="UNKNOWN" weightage="20" keywordseo="ramanan-laxinarayan">Ramanan Laxinarayan</keyword>, the Director of Centre of Disease Dynamics, Economics and Policy (CDDEP). According to him, the risk of vector-based vaccines in India is that there’s a strong possibility that people are already immune to certain adenoviruses because they’ve already been exposed to them. This results in the possibility that the vaccine won’t take. “Every idea out there, every platform has pluses and minuses,” he said. Ordinarily it takes at least five years to develop a viable vaccine. But in these unprecedented times, it’s possible that a solution could present itself in a matter of months. The front runners for a coronavirus vaccine The two US coronavirus vaccine candidates being developed by Pfizer — in collaboration with Fosum and Germany's BioNTech — and Moderna, are based on the genetic material of DNA protein 'spike'. “The jury is out there to see if it’s really going to work and even if it does work, I don’t think that’s a vaccine that India will really benefit from because these are very expensive vaccines,” said Shaw. The ones in the US may not be the best for Indian patients The US coronavirus vaccine candidates need to be stored at -80 degrees Celsius and have to be delivered intravenously. “We’re much more comfortable with a jab and a low-cost vaccine, which is what the Oxford and Chinese vaccines are all about. These are more typical and conventional vaccines,” she explained. China has the lead closely followed by the Indian project underway at Oxford China is currently leading the charge to develop a coronavirus vaccine. <a href="https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines">Cansino Biological</a> and the Beijing Institute of Biotechnology are using an Ebola-based candidate to develop a adenovirus type 5 vector coronavirus vaccine, currently in Phase-1 and Phase-2 of clinical trials. Another Chinese candidate vaccine is being developed by the Beijing Institute of Biological Products in partnership with <keyword id="522337" type="ORGANIZATION" weightage="20" keywordseo="Sinopharm">Sinopharm</keyword>, which is also conducting Phase 1 and Phase 2 trials simultaneously. Coming in second is the University of Oxford, which is using a non-replicating viral vector approach based on MERS, influenza, TB, chikungunya, Zika and others to develop its coronavirus vaccine. The Serum Institute of India (SII) — the world’s largest vaccine maker — is already manufacturing Oxford’s vaccine even though it doesn’t have approval yet. It's taking the risk of producing up to 400 million doses by the end of the year, if all goes well. Is India working on a coronavirus vaccine? Indian companies, including Biocon, have no intention of being left behind. They are also working on producing a coronavirus vaccine but it's going to take <a href="https://www.businessinsider.in/science/health/news/biocon-chairperson-kiran-mazumdar-shaw-says-indias-covid-19-vaccines-will-enter-clinical-trial-in-9-months/articleshow/75591805.cms">at least nine months</a> before they’re able to get to a clinic, according to Shaw. “The government of India is asking large companies to help the small vaccine biotech companies expedite and advance their programs,” she said. See also: <a href="https://www.businessinsider.in/science/health/news/biocon-chairperson-kiran-mazumdar-shaw-says-indias-covid-19-vaccines-will-enter-clinical-trial-in-9-months/articleshow/75591805.cms">Don’t hold your breath ⁠— Biocon founder Kiran Mazumdar Shaw says India's Covid-19 vaccine will enter clinical trials in 9 months</a> <a href="https://www.businessinsider.in/stock-market/news/moderna-skyrockets-16-to-record-high-after-fda-clears-coronavirus-vaccine-for-phase-2-study/articleshow/75603580.cms">Moderna skyrockets 16% to record high after FDA clears coronavirus vaccine for phase 2 study</a>

There are a lot of coronavirus vaccines in the works⁠— but these are the two that Indians should watch out for

<ul><li>“Even after India approves the coronavirus vaccine, it might not be possible to produce more than 10-20 million doses in the first year.”</li><li>The comments came from the Chairperson of Biocon in an exclusive chat with Business Insider.</li><li>Syngene, a Biocon subsidiary, is involved in accelerating a bunch of initiatives to develop a vaccine for the novel coronavirus that is spreading around the world.</li></ul>There are at least six vaccines under development in India, of the total 100 around the world including from the likes of Sanofi, Altimmune, and Pfizer. “Indian vaccine programmes will take some time before they get into the clinical trials, I think between 6 to 9 months depending on the programme. At least the ones we are working on, I don’t think they can get to clinics before 9 months,” Kiran Mazumdar Shaw, Founder and Executive Chairperson, Biocon told Business Insider. Vaccine development takes time due to the phases involved Shaw further said that vaccine development takes a lot of time because several phases are involved in it. In the first phase, a dose escalation is done to see what the ideal dose for an optimal immune response is. In the second phase, it is tested if the immune response can be done in all age groups. This is important as the first phase is conducted with young healthy volunteers who are at minimal risk. In the third phase, the vaccine is given to a larger population to ensure that the same immune response is given by everyone who is vaccinated. “One of the most important things of this phase is to check how long the immunity stays. This allows to determine how often a person will have to get revaccinated,” Shaw further noted. India will only be able to produce 10-20 million vaccines in 1 year Speaking about the production capacity, Shaw said that even after the vaccine is approved, India may not be able to produce more than 10-20 million doses in the first year, which is a negligible amount considering India’s population. See also: <a href="https://www.businessinsider.in/international/news/sanofi-one-of-the-largest-drug-makers-will-test-experimental-coronavirus-vaccine-on-humans-starting-september/articleshow/75571397.cms">Sanofi, one of the largest drug makers, will test experimental coronavirus vaccine on humans starting September</a> <a href="https://www.businessinsider.in/science/news/2-of-the-worlds-biggest-drugmakers-just-teamed-up-on-a-coronavirus-vaccine-and-theyre-aiming-to-launch-it-next-year/articleshow/75142796.cms">2 of the world's biggest drugmakers just teamed up on a coronavirus vaccine, and they're aiming to launch it next year</a>

Don’t hold your breath ⁠— Biocon founder Kiran Mazumdar Shaw says India's Covid-19 vaccine will enter clinical trials in 9 months

India’s richest women as per Hurun list: Kiran Mazumdar Shaw and Smita Crishna on top

<ul><li><keyword id="55796" type="PERSON" weightage="20" keywordseo="Kiran-Mazumdar-Shaw">Kiran Mazumdar Shaw</keyword>, chairperson and managing director of <keyword id="6358361" type="DEFINITION" weightage="20" keywordseo="biocon">Biocon</keyword>, said that she is willing to provide free testing kits for <keyword id="1754604" type="PERSON" weightage="20" keywordseo="coronavirus">coronavirus</keyword>.</li><li>Shaw mentioned that she is working with Apollo to figure out how they can provide testing for the deadly virus. </li><li>She is an advisor for Apollo’s Stay I project – where Apollo is building quarantine facilities. </li></ul><keyword id="25931" type="COMPANY" weightage="20" keywordseo="billionaire">Billionaire</keyword> entrepreneur and the founder of Biocon, Kiran Mazumdar Shaw said that her company is willing to provide free testing kits for coronavirus. During a conference call with the media for the launch of Apollo’s Project Stay I – an initiative to make way for 5,000 rooms as quarantine facilities across the country, Shaw mentioned that she is working with Apollo to figure out how they can provide testing for the deadly virus. During the call, Apollo’s joint managing director Sangita Reddy mentioned that Shaw created a WhatsApp group to get the industry leaders together and build solutions for Covid-19. Shaw is an advisor for Apollo’s Stay I project. “There’s a short window of opportunity for us to make a success out of this quarantine. Project Stay I is a very important initiative that is being embarked upon, It needs to be emulated by all the hospitals and hotel chains in the country. This is a step up model. People with mild, asymptomatic, as well as positive can be placed here and only serious cases can go to the ICU,” Shaw said during the call. “We need to be in a state of preparedness,” she said. Apollo has pooled 5000 rooms from Lemon Tree, Ginger and Oyo at a discount. These isolation rooms will be made available with medically supervised beds in Hyderabad, Chennai, Mumbai, Kolkata, Bangalore and Delhi. The project will start with approximately 500 in Bangalore, Chennai, Delhi, Kolkata, Mumbai, going up by 50 rooms every three days. See Also: <a href="https://www.businessinsider.in/india/news/apollo-hospitals-partners-with-oyo-zomato-and-sbi-and-others-to-offer-5000-quarantine-rooms-to-coronavirus-patients/articleshow/74887301.cms">Apollo Hospitals partners with Oyo, Zomato, SBI and others to offer 5,000 quarantine rooms to Coronavirus patients</a>

You Searched For "kiran mazumdar shaw coronavirus" and got 11 results

10 richest women in India in 2024

Ashmita Gupta

Kiran Mazumdar-Shaw to retire from Infosys board

ANI

Biocon Q1FY23 revenue up 23% at Rs 2,217 cr

IANS

Nykaa’s Falguni Nayar overtakes Kiran Mazumdar Shaw as the richest self-made Indian woman

Vaamanaa Sethi

Biocon’s Kiran Mazumdar Shaw, who debuted in the pharma industry with two employees and $500 becomes EY World Entrepreneur of the Year 2020

Prerna Sindwani

Catch Kiran Mazumdar Shaw at the Global Trends Festival 2020, speak about unlocking India's suppressed potential

BI India Bureau

India’s second richest woman nearly doubles her wealth to $4.6 billion during the COVID-19 pandemic

Preeti Soni

There are a lot of coronavirus vaccines in the works⁠— but these are the two that Indians should watch out for

Prabhjote Gill

Don’t hold your breath ⁠— Biocon founder Kiran Mazumdar Shaw says India's Covid-19 vaccine will enter clinical trials in 9 months

Rounak Jain

India’s richest women as per Hurun list: Kiran Mazumdar Shaw and Smita Crishna on top

Rounak Jain

Billionaire Kiran Mazumdar Shaw says she is willing to provide free testing for coronavirus

Sanchita Dash

Popular Keywords

Buying Guides